Abstract
Eisenmenger syndrome is associated with irreversible increase in pulmonary vascular resistance causing reduced survival. Bosentan, a non-selective endothelin receptor antagonist is the commonly used specific pulmonary arterial hypertension drug in Eisenmenger syndrome. In this paper, we present a case of recurrent gastrointestinal bleeding in a 23-year-old female with Eisenmenger syndrome who was only under bosentan treatment, which has not been reported previously. Most common adverse effect of bosentan is elevation in the liver enzymes however, bleeding complication is very rare. On the contrary, it was proposed that bosentan might be a potential protector against hyperacidity and mucosal erosion that occur as a consequence of stress. Although the mechanistic relationship of bleeding tendency and role of Eisenmenger syndrome concomitant with bosentan treatment is far from conclusive statement for now, this association warrants and should draw attention of clinicians and researches in this field.
Keywords: Bosentan, congenital heart disease, eisenmenger, gastrointestinal bleeding, pulmonary hypertension.
Current Drug Safety
Title:Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Volume: 8 Issue: 4
Author(s): Ibrahim Sari, Hakan Cam, M. Sait Dag, Erdal Durmus, Tarik Kivrak, Kursat Tigen and Vedat Davutoglu
Affiliation:
Keywords: Bosentan, congenital heart disease, eisenmenger, gastrointestinal bleeding, pulmonary hypertension.
Abstract: Eisenmenger syndrome is associated with irreversible increase in pulmonary vascular resistance causing reduced survival. Bosentan, a non-selective endothelin receptor antagonist is the commonly used specific pulmonary arterial hypertension drug in Eisenmenger syndrome. In this paper, we present a case of recurrent gastrointestinal bleeding in a 23-year-old female with Eisenmenger syndrome who was only under bosentan treatment, which has not been reported previously. Most common adverse effect of bosentan is elevation in the liver enzymes however, bleeding complication is very rare. On the contrary, it was proposed that bosentan might be a potential protector against hyperacidity and mucosal erosion that occur as a consequence of stress. Although the mechanistic relationship of bleeding tendency and role of Eisenmenger syndrome concomitant with bosentan treatment is far from conclusive statement for now, this association warrants and should draw attention of clinicians and researches in this field.
Export Options
About this article
Cite this article as:
Sari Ibrahim, Cam Hakan, Dag Sait M., Durmus Erdal, Kivrak Tarik, Tigen Kursat and Davutoglu Vedat, Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan, Current Drug Safety 2013; 8 (4) . https://dx.doi.org/10.2174/1574886319999990001
DOI https://dx.doi.org/10.2174/1574886319999990001 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Electrochemical Detection and Sensing of Reactive Oxygen Species
Current Organic Chemistry Metabolomics of Serum Peptides
Protein & Peptide Letters Neutrophil Cell Count is Related to Hypertension in Workers: A Cross- Sectional Study
Vascular Disease Prevention (Discontinued) P2 Receptors in Renal Autoregulation
Current Vascular Pharmacology Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview
Current Clinical Pharmacology The Physiology and Pathophysiology of a Novel Angiotensin Receptor-binding Protein ATRAP/Agtrap
Current Pharmaceutical Design Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms
Current Vascular Pharmacology Severe OSA Leading to Long Pauses in 24-h Holter ECG Reversed with CPAP
Current Cardiology Reviews A Variant in the Endoglin Gene is Associated with the Development of Sporadic Intracranial Aneurysms
Current Neurovascular Research Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews Systemic Inflammation Induces Endothelial Dysfunction in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Use of Antihistamines in Ocular Therapy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research PDE5 Inhibitors in the Treatment of LUTS
Current Pharmaceutical Design Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Editorial (Thematic Issue: Antihypertensive Treatment in the Elderly)
Cardiovascular & Hematological Agents in Medicinal Chemistry Atorvastatin Inhibits Advanced Glycation End Products (AGE)-Induced C-Reactive Expression in Hepatoma Cells by Suppressing Reactive Oxygen Species Generation
Vascular Disease Prevention (Discontinued) High Altitude Pulmonary Hypertension
Cardiovascular & Hematological Disorders-Drug Targets Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets